Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study

Objective To determine the frequency of prescriptions for short term use of oral corticosteroids, and adverse events (sepsis, venous thromboembolism, fractures) associated with their use. Design Retrospective cohort study and self controlled case series. Setting Nationwide dataset of private insurance claims. Participants Adults aged 18 to 64 years who were continuously enrolled from 2012 to 2014. Main outcome measures Rates of short term use of oral corticosteroids defined as less than 30 days duration. Incidence rates of adverse events in corticosteroid users and non-users. Incidence rate ratios for adverse events within 30 day and 31-90 day risk periods after drug initiation. Results Of 1 548 945 adults, 327 452 (21.1%) received at least one outpatient prescription for short term use of oral corticosteroids over the three year period. Use was more frequent among older patients, women, and white adults, with significant regional variation (all P<0.001). The most common indications for use were upper respiratory tract infections, spinal conditions, and allergies. Prescriptions were provided by a diverse range of specialties. Within 30 days of drug initiation, there was an increase in rates of sepsis (incidence rate ratio 5.30, 95% confidence interval 3.80 to 7.41), venous thromboembolism (3.33, 2.78 to 3.99), and fracture (1.87, 1.69 to 2.07), which diminished over the subsequent 31-90 days. The increased risk persisted at prednisone equivalent doses of less than 20 mg/day (incidence rate ratio 4.02 for sepsis, 3.61 for venous thromboembolism, and 1.83 for fracture; all P<0.001). Conclusion One in five American adults in a commercially insured plan were given prescriptions for short term use of oral corticosteroids during a three year period, with an associated increased risk of adverse events.

[1]  Kathryn Majors-Foley Oral Prednisolone in the Treatment of Acute Gout: A Pragmatic, Multicenter, Double-Blind, Randomized Trial , 2016 .

[2]  T. Rainer,et al.  Oral Prednisolone in the Treatment of Acute Gout: A Pragmatic, Multicenter, Double-Blind, Randomized Trial. , 2016, Annals of internal medicine.

[3]  Charles King,et al.  2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2016, Arthritis & rheumatology.

[4]  L. Ackerson,et al.  Oral steroids for acute radiculopathy due to a herniated lumbar disk: a randomized clinical trial. , 2015, JAMA.

[5]  Raveendhara R. Bannuru,et al.  American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2015 .

[6]  A. Escalante,et al.  Glucocorticoid Dose Thresholds Associated With All‐Cause and Cardiovascular Mortality in Rheumatoid Arthritis , 2014, Arthritis & rheumatology.

[7]  N. Ishizuka,et al.  Rates of Serious Intracellular Infections in Autoimmune Disease Patients Receiving Initial Glucocorticoid Therapy , 2013, PloS one.

[8]  A. Elixhauser,et al.  Origin of Adverse Drug Events in U.S. Hospitals, 2011 , 2013 .

[9]  E. Horváth-Puhó,et al.  Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. , 2013, JAMA internal medicine.

[10]  P. Souverein,et al.  Use of oral glucocorticoids and the risk of pulmonary embolism: a population-based case-control study. , 2013, Chest.

[11]  C. Siegel,et al.  Quality improvement in inflammatory bowel disease. , 2013, Gastroenterology & hepatology.

[12]  C. Deal,et al.  Prevalence of oral glucocorticoid usage in the United States: A general population perspective , 2013, Arthritis care & research.

[13]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[14]  W. Baine,et al.  The Agency for Healthcare Research and Quality , 2006, Italian Journal of Public Health.

[15]  V. Chopra,et al.  Triggers of Hospitalization for Venous Thromboembolism , 2012, Circulation.

[16]  Tom Reynders,et al.  Prednisone affects inflammation, glucose tolerance, and bone turnover within hours of treatment in healthy individuals. , 2012, European journal of endocrinology.

[17]  Malcolm Maclure,et al.  Design considerations in an active medical product safety monitoring system , 2012, Pharmacoepidemiology and drug safety.

[18]  L. Crofford,et al.  Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. , 2011, Clinical therapeutics.

[19]  G. Rebecca,et al.  American College of Rheumatology 2010 Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 2011 .

[20]  P. Wiffen,et al.  Antidepressants for neuropathic pain: a Cochrane review , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[21]  B. Rimer,et al.  Triangulating Differential Nonresponse by Race in a Telephone Survey , 2007, Preventing chronic disease.

[22]  T. Therneau,et al.  Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. , 2007, Arthritis and rheumatism.

[23]  Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. , 2007, The Journal of allergy and clinical immunology.

[24]  T. Zuberbier,et al.  Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. , 2006, The Journal of allergy and clinical immunology.

[25]  A. Muraro,et al.  Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. , 2006, The Journal of allergy and clinical immunology.

[26]  Jeffrey R Curtis,et al.  Population-based assessment of adverse events associated with long-term glucocorticoid use. , 2006, Arthritis and rheumatism.

[27]  Patrick Musonda,et al.  Tutorial in biostatistics: the self‐controlled case series method , 2006, Statistics in medicine.

[28]  J. Cidlowski,et al.  Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. , 2005, The New England journal of medicine.

[29]  J. Avorn,et al.  A review of uses of health care utilization databases for epidemiologic research on therapeutics. , 2005, Journal of clinical epidemiology.

[30]  Hang Lee,et al.  Effects of Low‐Dose Prednisone on Bone Metabolism , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  T. MacDonald,et al.  Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease , 2004, Annals of Internal Medicine.

[32]  A. Bertolotto,et al.  Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. , 2004, The Journal of clinical endocrinology and metabolism.

[33]  B. Joffe,et al.  Glucocorticoids and insulin sensitivity in rheumatoid arthritis. , 2004, The Journal of rheumatology.

[34]  B. Gudbjornsson,et al.  Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice , 2002, Annals of the rheumatic diseases.

[35]  J. Eisman,et al.  Glucocorticoid-Induced Osteoporosis: Basic Pathological Mechanisms, Clinical Features, and Management in the New Millennium , 2001 .

[36]  L. Bouter,et al.  Conservative treatment options for carpal tunnel syndrome: a systematic review of randomised controlled trials , 2002, Journal of Neurology.

[37]  L Abenhaim,et al.  Use of oral corticosteroids in the United Kingdom. , 2000, QJM : monthly journal of the Association of Physicians.

[38]  A. Adelman Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. , 1999, The Journal of family practice.

[39]  D. Niewoehner,et al.  Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. , 1999, The New England journal of medicine.

[40]  P. Delmas,et al.  The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica. , 1998, British journal of rheumatology.

[41]  C. Steiner,et al.  Comorbidity measures for use with administrative data. , 1998, Medical care.

[42]  Third Expert Panel on theDiagnosis,et al.  Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma , 1997 .

[43]  M. Singer,et al.  Oxford Handbook of Critical Care , 1997 .

[44]  M. Pringle,et al.  Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study , 1996, BMJ.

[45]  J. Avorn,et al.  Glucocorticoids and the risk for initiation of hypoglycemic therapy. , 1994, Archives of internal medicine.

[46]  M. Prummel,et al.  Beclomethasone inhalation decreases serum osteocalcin concentrations. , 1991, BMJ.

[47]  L. Mosekilde,et al.  The effects of high-dose glucocorticoid administration on serum bone gamma carboxyglutamic acid-containing protein, serum alkaline phosphatase and vitamin D metabolites in normal subjects. , 1988, Bone and mineral.

[48]  B. Korelitz,et al.  Clinical trials in ulcerative colitis: II. Historical review. , 1988, The American journal of gastroenterology.

[49]  B. Littenberg,et al.  A controlled trial of methylprednisolone in the emergency treatment of acute asthma. , 1986, The New England journal of medicine.

[50]  R. Macdermott,et al.  Immunosuppressive effects of low doses of glucocorticoids: effects on autologous and allogeneic mixed leukocyte reactions. , 1980, Journal of immunology.

[51]  F. H. Tyler,et al.  Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. , 1977, The American journal of medicine.

[52]  F. Carone,et al.  Acute pancreatic lesions in patients treated with ACTH and adrenal corticoids. , 1957, The New England journal of medicine.

[53]  W. Charney,et al.  New antiarthritic steroids. , 1955, Science.

[54]  J. J. Bunim,et al.  Studies on metacortandralone and metacortandracin in rheumatoid arthritis; antirheumatic potency, metabolic effects, and hormonal properties. , 1955, Journal of the American Medical Association.

[55]  R. E. Stone,et al.  Deoxycortone with ascorbic acid versus adrenocorticotropic hormone in rheumatoid arthritis. , 1949, Lancet.